JP will join and present on a panel exploring arbitration in the life sciences sector. As the sector continues to experience rapid growth, so does the number of related arbitrations. Many pharma and biotech projects are highly complex, span many years, and involve numerous stakeholders, providing fertile ground for disputes. The panel will explore why international arbitration is well suited to resolve licensing, joint-venture, and co-marketing disputes that accompany these projects.
Topics to be covered include:
- The characteristics that make arbitration a better dispute resolution mechanism than litigation in the life sciences sector
- Drafting arbitration clauses and formulating dispute avoidance strategies in the life sciences sector
- Getting to grips with complex pharmaceutical legislation and regulatory policy
